Advertisement
Research Article|Articles in Press, 100460

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor Based Systemic Therapy in BRAF-Mutation Positive Non-Small Cell Lung Cancer

Open AccessPublished:January 09, 2023DOI:https://doi.org/10.1016/j.jtocrr.2022.100460
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor Based Systemic Therapy in BRAF-Mutation Positive Non-Small Cell Lung Cancer
Previous Articleerratum
Next ArticleOsimertinib in Non-Small Cell Lung Cancer (NSCLC) with Atypical EGFR Activating Mutations: A Retrospective Multicenter Study
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Introduction

      BRAF mutations (present in 2-3% of non-small cell lung cancer) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns and effectiveness of targeted BRAF-inhibiting and immune checkpoint inhibitor (ICI)-based systemic therapies, yet this is required for appropriate treatment decisions which optimize patient outcome.

      Methods

      Demographic, clinical, treatment and outcome data of BRAF-mutation positive diagnosed between 2018 and 2022 were identified from the Glans-Look Lung Cancer Research database and included in this analysis.

      Results

      53 BRAF-mutations positive patients were identified (V600E, n=35; Non-V600E, n=18). 46 patients (87%) were diagnosed with metastatic disease, of which 61% were treated with systemic anti-cancer therapy, which significantly improved overall survival (34.1 vs. 2.2 months, p=0.01). ICI-based regimens showed effectiveness in the first-line setting for both V600E and Non-V600E cohorts (Objective response rate (ORR): 38-43%; median progression free survival (RW-mPFS): 10.5-10.8 months, respectively). Targeted dual BRAF/MEK-inhibition also showed effectiveness in the first-line setting for V600E patients (ORR: 33%, RW-mPFS: 15.2 months).

      Conclusion

      This study of real-world patients with BRAF-mutations confirms the importance of effective systemic therapies. Both dual targeted BRAF/MEK-inhibition and ICI-based regimens show evidence of benefit in this population and demonstrate that real-world populations can experience similar clinical response and outcome to clinical trial cohorts on these treatment regimens. Future studies to clarify the role co-mutations on response to both dual targeted BRAF/MEK-inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome.

      Keywords

      Article info

      Publication history

      Accepted: December 29, 2022
      Received in revised form: December 28, 2022
      Received: November 28, 2022

      Publication stage

      In Press Journal Pre-Proof

      Footnotes

      Funding Disclosure: This work was supported by a philanthropic donation to the Glans-Look Lung Cancer database.

      Conflict of Interest:

      Dr. Navani reports personal consulting fees from Kwoya Kirin, Novotech PTY, Pfizer, Astra Zeneca, EMD Serono and IPSOS. Dr. Pabani reports grants from Bristol Myers Squibb, honoraria from AstraZeneca, Bristol Myers Squibb, Pfizer, Roche and Novartis, and advisory board participation with AstraZeneca, Bristol Myers Squibb and Novartis. The other authors report no relevant disclosures.

      CRediT Statement

      Amanda Gibson: Conceptualization, Methodology, Formal Analysis, Investigation, Data Curation, Writing – Original Draft

      Michelle Dean: Investigation, Resources, Data Curation, Writing – Review & Editing, Project Administration

      Guillermo Martos: Investigation, Data Curation, Writing – Review & Editing

      Winson Cheung: Supervision

      Aliyah Pabani: Conceptualization, Validation, Writing – Review & Editing

      Vishal Navani: Conceptualization, Methodology, Validation, Writing – Review & Editing, Supervision

      Identification

      DOI: https://doi.org/10.1016/j.jtocrr.2022.100460

      Copyright

      © 2023 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX